Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
… biotech company advancing our proprietary Axiomer RNA-editing platform technology. We are ProQR We are ProQR We … company dedicated to changing lives by developing RNA therapies for severe rare and common diseases. We focus … and Cambridge, Massachusetts, USA. Learn more about RNAtherapy and our Axiomer technology . We are on a mission We …
… of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing … where our scientists discover and test our novel RNA therapies. Our passion lies in discovering the latest RNA … technology. Internal link View this technology RNAtherapy Our antisense oligonucleotides are designed to …
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
